Latham & Watkins has advised Arcus Biosciences. Gunderson Dettmer has advised the underwriters. Arcus Biosciences, a clinical-stage, global biopharmaceutical company listed on the NYSE under the...
Arcus Biosciences Completes $287.5 Million Common Stock Offering
Wolfspeed Reduces Debt Through Comprehensive Financial Restructuring Agreement
Latham & Watkins has advised Wolfspeed, while Kirkland & Ellis and Haynes Boone have advised Renesas Electronics Corporation and its subsidiary. Wolfspeed, Inc. has completed a...
Figma Announces $1.2 Billion Initial Public Offering
Fenwick has advised Figma on the offering, Latham & Watkins has advised the underwriters. Whalen LLP has acted as counsel for the selling stockholders. Figma, a...
CARGO Therapeutics’ $281.3 Million Initial Public Offering
Wilson Sonsini Goodrich & Rosati and Latham & Watkins advised CARGO Therapeutics, Inc. on the offering, and Cooley advised the underwriters. CARGO Therapeutics, Inc. (CARGO) (Nasdaq:CRGX)...
Coherus BioSciences’ $57.5 Million Follow-On Offering
Latham & Watkins advised Coherus BioSciences, and Davis Polk advised J.P. Morgan Securities LLC and Citigroup Global Markets Inc. on the offering. Coherus BioSciences, Inc. (“Coherus”, Nasdaq:...
4D Molecular Therapeutics’ $120 Million Common Stock Offering
Latham & Watkins advised 4D Molecular Therapeutics, while Cooley advised the underwriters for the offering. 4D Molecular Therapeutics, Inc. has announced that it priced an upsized...
BridgeBio Pharma’s $150 Million Common Stock Public Offering
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
Wolfspeed’s $1,525 Million Convertible Senior Notes Offering
Latham & Watkins represented Wolfspeed, while Davis Polk advised the representatives of the initial purchasers in the offering. Wolfspeed, Inc. (NYSE: WOLF), a global leader in Silicon...
Alpine Immune Sciences’ $100 Million Shares Offering
Wilson Sonsini Goodrich & Rosati represented Alpine, while Latham & Watkins represented to underwriters in the offering. Alpine Immune Sciences, Inc. (Nasdaq: ALPN) has announced the pricing...
Chinook Therapeutics’ $105 Million Public Offering
Latham & Watkins represented the underwriters in the offering. Chinook Therapeutics, Inc. (Nasdaq: KDNY) has announced the pricing of its underwritten public offering of 6,428,572 shares...

































